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A mouse model was used to test the hypothesis that antibiotics with activity against anaerobes promote
overgrowth of extended-spectrum -lactamase-producing Klebsiella pneumoniae strains in stool. Subcutaneous
clindamycin consistently promoted establishment of high-density colonization, whereas piperacillin-tazobac-
tam, ceftriaxone, and ceftazidime promoted colonization only when a large inoculum and/or more resistant
strain was administered.
Use of broad-spectrum cephalosporins has been associated
with the emergence of extended-spectrum -lactamase (ESBL)-
producing gram-negative bacilli (9–11). Although non-cephalos-
porin antibiotics have also been associated with ESBLs (7, 9, 14),
the mechanisms by which these agents promote ESBL-producing
organisms are not well defined. Because intestinal anaerobes pro-
vide colonization resistance against overgrowth of potential
pathogens (2, 8, 13), we hypothesized that antibiotics that have
been shown to reduce levels of intestinal anaerobes (i.e., clinda-
mycin, piperacillin-tazobactam, ceftriaxone, and ceftazidime) (1,
2, 13) would promote overgrowth of ESBL-producing Klebsiella
pneumoniae strains in mice, whereas antibiotics that minimally
affect anaerobes (i.e., cefepime, levofloxacin, and aztreonam) (2,
5, 13) would not.
Two K. pneumoniae bloodstream isolates were studied.
Strain P62 produces an SHV ESBL and P10045 produces
TEM-1 and an SHV ESBL. The bla ESBL genes of both
strains have mutations at amino acid positions 238 and 240,
indicating that they encode SHV-5 or derivatives. The broth
dilution MICs for P62 and P10045, respectively, were as fol-
lows: ceftazidime, 16 and 1,250 g/ml; piperacillin-tazobactam,
4 and 156 g/ml; ceftriaxone, 4 and 78 g/ml; levofloxacin,
0.125 and 4 g/ml; cefepime, 0.75 and 8 g/ml; and aztreo-
nam, 128 and 2,500 g/ml.
The experimental protocol was approved by the Cleveland
Veterans Affairs Medical Center’s Animal Care Committee.
Female CF1 mice (Harlan Sprague-Dawley, Indianapolis,
Ind.) weighing 25 to 30 g were housed individually. On exper-
iment day 0, esophageal inoculation of 103 CFU of ESBL-
producing K. pneumoniae suspended in 0.5 ml of phosphate-
buffered saline was performed with a stainless steel feeding
tube (Perfektum; Popper & Sons, New Hyde Park, N.Y.). On
experiment day 5, a second dose of 108 CFU was administered
to all groups except the clindamycin group.
From experiment day 2 (2 days before the first ESBL-
producing K. pneumoniae administration) through day 8, sub-
cutaneous injection (0.2-ml total volume) of saline, clindamy-
cin (1.4 or 16.8 mg/day), piperacillin-tazobactam (8 or 96 mg/
day), ceftriaxone (2.0 or 12.4 mg/day), ceftazidime (3.0 or 36.8
mg/day), cefepime (2.0 or 24 mg/day), levofloxacin (0.375 or
4.7 mg/day), or aztreonam (3.0 or 37.5 mg/day) was adminis-
tered at 12-h intervals. The lower dose of antibiotic was based
on the daily dose recommended for human adults (in milli-
grams per kilogram of body weight), and the higher dose was
the human equivalent dose calculated by the technique of
Freireich et al. (6). The dose of levofloxacin was based on the
750-mg/day human dose. Stool samples were collected at base-
line and at 2- to 7-day intervals after inoculation of ESBL-
producing K. pneumoniae. The density of pathogens was mea-
sured as previously described, except samples were plated onto
MacConkey agar (Difco Laboratories, Detroit, Mich.) supple-
mented with ceftazidime (10 g/ml) (3).
The experiments were performed twice with a total of six or
seven mice per group. For each experiment, randomly selected
ceftazidime-resistant gram-negative bacilli from stool were
subjected to speciation and susceptibility testing by VITEK
(bioMerieux, Inc., Hazelwood, Mo.). For the lower-antibiotic-
dose experiments, the density of colonization was monitored
after discontinuation of antibiotic treatment to assess clear-
ance of the ESBL-producing K. pneumoniae strains. Data were
analyzed with SPSS version 10.0 (Chicago, Ill.). A Kruskal-
Wallis test was performed to evaluate for significant differ-
ences among the groups on days 3, 5, 8, and 11. Because the
data did not deviate substantially from normality, a one-way
analysis of variance with a post hoc Scheffe correction to adjust
for multiple comparisons was performed.
The effect of antibiotics on the establishment of colonization
is shown in Fig. 1. At baseline, none of the mice had detectable
ceftazidime-resistant gram-negative bacilli (level of detection,
2 to 2.5 log10 CFU/g). After the 10
3-CFU inoculum of either
strain (day 0), clindamycin at both dosages promoted persis-
tent high-density colonization in comparison to the saline con-
trols (P  0.0001). The only other significant promotion of
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overgrowth after the 103 inoculum occurred when the more
resistant P10045 strain was administered in combination with
higher dosages of ceftazidime (P  0.0001 on days 3 and 5) or
piperacillin-tazobactam (P  0.066 on day 3 and 0.012 on day
5) (Fig. 1D).
After the 108-CFU ESBL-producing K. pneumoniae inocu-
lum on day 5, the lower dosage of piperacillin-tazobactam
promoted high-density colonization of both strains in compar-
ison to the controls (P  0.02 on days 8 and 11) (Fig. 1A and
B), but at the higher antibiotic dosage, only the P10045 strain
was promoted (P  0.001) (Fig. 1D). After the 108-CFU in-
oculum, the lower dosage of ceftazidime promoted significant
overgrowth of the P10045 strain in comparison to the controls
(P  0.02) and resulted in a trend toward increased density of
the P62 strain (P  0.066 on day 8); the higher dosage of
ceftazidime promoted overgrowth of both strains (P  0.025).
After the 108-CFU inoculum, the lower dosage of ceftriaxone
promoted overgrowth of both strains in comparison to the
controls (P  0.02), but at the higher dosage, only P62 was
promoted (P  0.9 on day 8 and 0.01 on day 11). After dis-
continuation of antibiotics, the density of colonization de-
creased for those treatment groups that promoted overgrowth
(Fig. 1A and B). Aztreonam, levofloxacin, and cefepime did
not promote colonization of either strain after the 103- or
FIG. 1. Effect of subcutaneous antibiotic administration on the establishment of colonization with of ESBL-producing K. pneumoniae in mice.
Densities of ESBL-producing K. pneumoniae in stool are shown for strain P62 with low-dose antibiotics (equal to human doses on a milligram-per
kilogram basis) (A), strain P10045 with low-dose antibiotics (B), strain P62 with corrected human-equivalent doses of antibiotics (C), and strain
P10045 with corrected doses of antibiotics (D). Mice received subcutaneous injections of antibiotics every 12 h from day2 to day 8. Mice received
103 CFU of ESBL-producing K. pneumoniae by esophageal inoculation on day 0 and 108 CFU on day 5. If ESBL-producing K. pneumoniae
organisms were not detected in stool, the lower limit of detection (2 log10 CFU/g) was assigned.
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108-CFU inoculums (P  0.05 for all groups in comparison to
controls). Analysis of several stool isolates of ceftazidime-re-
sistant gram-negative bacilli yielded K. pneumoniae strains with
susceptibility patterns identical to those of the original strains.
Our findings support the hypothesis that the indigenous an-
aerobic microflora inhibit colonization with Enterobacteriaceae
such as ESBL-producing K. pneumoniae. Antibiotics with min-
imal activity against intestinal anaerobes (i.e., cefepime, az-
treonam, and levofloxacin) did not promote ESBL-producing
K. pneumoniae colonization, whereas an antianaerobic agent
with negligible activity against Enterobacteriaceae (i.e., clinda-
mycin) promoted high-density colonization. The effect of an-
tibiotics such as piperacillin-tazobactam, ceftriaxone, and
ceftazidime on establishment of colonization suggests a bal-
ance between inhibitory activity against ESBL-producing K.
pneumoniae strains and promotion due to antianaerobic activ-
ity. For these antibiotics, overgrowth only occurred when a
larger inoculum or more-resistant strain (P10045) was admin-
istered. Piperacillin-tazobactam demonstrated a similar inocu-
lum effect with regard to vancomycin-resistant Enterococcus
colonization in mice (4). It is notable that the higher dose of
ceftazidime, but not ceftriaxone, promoted overgrowth of the
P10045 strain; this may due to the higher level of resistance of
P10045 to ceftazidime (ceftazidime and ceftriaxone MICs,
1,250 and 78 g/ml, respectively) and greater biliary excretion
of ceftriaxone (12).
Our findings have important clinical implications if validated
in humans. A variety of antibiotics with antianaerobic activity
are likely to facilitate transmission by promoting intestinal
colonization with ESBL-producing K. pneumoniae. Anti-
anaerobic antibiotics with minimal activity against ESBL-pro-
ducing organisms (e.g., clindamycin) should be avoided when
possible in outbreak settings. Formulary switches from broad-
spectrum cephalosporins to antianaerobic agents with activity
against ESBL-producing organisms (e.g., piperacillin-tazobac-
tam) may be effective in part because the inhibitory activity of
these agents may be sufficient to prevent the initial establish-
ment of colonization. For patients with established high-den-
sity colonization, however, agents such as piperacillin-tazobac-
tam may promote persistent high-density colonization and
therefore transmission.
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